PT - JOURNAL ARTICLE AU - Elizabeth Ford AU - Harley Parfitt AU - Ian McCheyne AU - István Z. Kiss AU - Ruth Sellers TI - Risk factors and symptom clusters for Long Covid: analysis of United Kingdom symptom tracker app data AID - 10.1101/2022.11.14.22282285 DP - 2022 Jan 01 TA - medRxiv PG - 2022.11.14.22282285 4099 - http://medrxiv.org/content/early/2022/11/14/2022.11.14.22282285.short 4100 - http://medrxiv.org/content/early/2022/11/14/2022.11.14.22282285.full AB - Background Long Covid, characterised by symptoms after Covid-19 infection which persist for longer than 12 weeks, is becoming an important societal and economic problem. As Long Covid was novel in 2020, there has been debate regarding its aetiology and whether it is one, or multiple, syndromes. This study assessed risk factors associated with Long Covid and examined symptom clusters that might indicate sub-types.Methods 4,040 participants reporting for >4 months in the Covid Symptom Study App were included. Multivariate logistic regression was undertaken to identify risk factors associated with Long Covid. Cluster analysis (K-modes and hierarchical agglomerative clustering) and factor analysis were undertaken to investigate symptom clusters.Results Long Covid affected 13.6% of participants. Significant risk factors included being female (P < 0.01), pre-existing poor health (P < 0.01), and worse symptoms in the initial illness. A model incorporating sociodemographics, comorbidities, and health status predicted Long Covid with an accuracy (AUROC) of 76%. The three clustering approaches gave rise to different sets of clusters with no consistent pattern across methods.Conclusions Our model of risk factors may help clinicians predict patients at higher risk of Long Covid, so these patients can rest more, receive treatments, or enter clinical trials; reducing the burden of this long-term and debilitating condition. No consistent subtypes were identified.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study received funding from the University of Sussex Higher Education Innovation Funding Account.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This project proposal (no.1146) to use the SAIL databank was approved by the SAIL Information Governance Review Panel (IGRP) on 16th June 2020.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data are held securely in the SAIL databank and are not openly accessible to other researchers, except with a project proposal and data access request made directly to SAIL. https://saildatabank.com/